← Back to Treatments
🏅 FDA Orphan Designation

Zenapax

Daclizumab

Manufacturer: Hoffmann-La Roche, Inc.

Indicated for:
Vein of Galen malformationOrphanOBSOLETE: Graft rejection after lung transplantation

FDA-Approved Indications (2)

Vein of Galen malformationOrphan Designation

Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.

Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids

Population: patients receiving renal transplants

Indications & Usage

Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.

💙 Support Programs

View all →
Zenapax
Hoffmann-La Roche, Inc.
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.